Compare AbbVie Inc (ABBV) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs KB Financial Group, Inc. — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while KB Financial Group, Inc. trades at $114.46 (market cap $39.97B). The key difference: AbbVie Inc is far larger — about 11.3× KB Financial Group, Inc.'s market cap. Which is the better fit depends on your goals.
| ABBV | KB | |
|---|---|---|
Market Cap | $449.91B | $39.97B |
Sector | Health | Financials |
52-Week High | $261.07 | $118.21 |
52-Week Low | $184.85 | $77.50 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
KB trades at $115.48, up 5.61% today, showing strong momentum near its 52-week high. Recent quarters have consistently beaten earnings expectations, with Q1 2026 EPS of $3.49 surpassing estimates. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust revenue growth to $21.23T in 2025 and a healthy net income margin of 27.82%.
Outlook remains positive given earnings beats and valuation appeal with a P/E of 10.95, though risks include volatile cash flows and high interest expenses. Analyst sentiment is mixed with 33% buy ratings, suggesting cautious optimism for continued performance if execution aligns with growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
